Nitro-Dur Shortage Update: What Patients Need to Know in 2026

Patients who rely on Nitro-Dur (nitroglycerin transdermal patches) for daily angina management deserve a clear picture of current availability in 2026 — not confusing headlines about a drug shortage that may not apply to their specific medication form. This post breaks down exactly what's happening with nitroglycerin supply and what it means for Nitro-Dur patients specifically.

What Is the Current Status of Nitroglycerin Supply in 2026?

As of 2026, the nitroglycerin supply situation is nuanced and formulation-specific. The most significantly affected forms have been sublingual tablets (such as Nitrostat) and injectable nitroglycerin used in hospitals. These formulations have experienced intermittent shortages driven by manufacturing constraints, raw material sourcing challenges, and a heavily concentrated supplier market.

Nitro-Dur and other nitroglycerin transdermal patches have generally been less affected than sublingual or injectable forms. However, that doesn't mean patch availability is problem-free. Patients in some regions report intermittent stock-outs at their local pharmacies — typically not due to a national shortage, but rather localized distribution and ordering cycle gaps.

Why Are Nitroglycerin Products Prone to Shortages?

Several structural factors make the nitroglycerin supply chain fragile:

Few active pharmaceutical ingredient (API) suppliers: Nitroglycerin requires specialized manufacturing conditions — it is, after all, an explosive compound in pure form. Only a limited number of facilities worldwide can safely produce pharmaceutical-grade nitroglycerin.

Low profit margins on generics: Generic nitroglycerin is inexpensive. Low profit margins reduce the financial incentive for pharmaceutical companies to maintain large manufacturing buffers or to invest heavily in capacity expansion.

Market concentration: When just one or two manufacturers dominate a product — as Pfizer does with Nitrostat sublingual tablets — any disruption at that manufacturer ripples across the entire supply.

Cascading demand shifts: When sublingual tablets become scarce, some physicians switch patients to patches or sprays, creating surge demand in those formulations even when they weren't originally in shortage.

How Does the Shortage Affect Nitro-Dur Patients Specifically?

For patients using Nitro-Dur for daily angina prevention, the main practical concern is not a national crisis but rather unpredictable local availability. You might find your usual pharmacy out of stock one month and fully stocked the next. Specific strength variations (like 0.4 mg/hr) may be more affected than others if a particular manufacturer experiences a production delay.

What Can Patients Do Right Now?

Use medfinder: medfinder.com contacts pharmacies near you to find which ones have your prescription in stock — far faster than calling each one yourself.

Request generic substitution: Ask your pharmacist to substitute a generic nitroglycerin patch if Nitro-Dur brand is unavailable. Generic patches are bioequivalent.

Refill early: Don't wait until you have only 2–3 days of patches left. Try to refill with at least a week to spare so you have time to search if your primary pharmacy is out of stock.

Consider mail-order: A 90-day supply through mail-order pharmacy reduces the frequency of potential stock-out situations.

Talk to your cardiologist: If you've experienced repeated trouble finding Nitro-Dur, your doctor may adjust your prescription to allow broader generic substitution or consider an alternative long-acting nitrate.

Where to Monitor Official Shortage Status

The FDA maintains the official drug shortage database at FDA.gov, which you can search by drug name. ASHP (American Society of Health-System Pharmacists) also maintains detailed shortage data with clinical context. And if you're looking for what to do when Nitro-Dur is unavailable, our guide on Nitro-Dur alternatives covers your options in detail.